Insider Selling: Zai Lab (NASDAQ:ZLAB) CEO Sells 24,543 Shares of Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Ying Du sold 24,543 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $17.46, for a total value of $428,520.78. Following the completion of the transaction, the chief executive officer directly owned 1,192,840 shares in the company, valued at approximately $20,826,986.40. This represents a 2.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ying Du also recently made the following trade(s):

• On Thursday, May 14th, Ying Du sold 50,000 shares of Zai Lab stock. The shares were sold at an average price of $20.09, for a total transaction of $1,004,500.00.
• On Monday, April 6th, Ying Du sold 2,653 shares of Zai Lab stock. The stock was sold at an average price of $20.45, for a total transaction of $54,253.85.
• On Thursday, April 2nd, Ying Du sold 5,576 shares of Zai Lab stock. The shares were sold at an average price of $20.39, for a total transaction of $113,694.64.

Zai Lab Stock Up 2.3%

NASDAQ ZLAB traded up $0.41 on Monday, reaching $18.41. The company had a trading volume of 944,868 shares, compared to its average volume of 821,367. The stock has a market capitalization of $2.09 billion, a PE ratio of -11.36 and a beta of 0.79. Zai Lab Limited Unsponsored ADR has a 12 month low of $15.96 and a 12 month high of $41.20. The firm’s 50 day moving average price is $19.40 and its 200 day moving average price is $18.96.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings data on Wednesday, April 1st. The company reported ($0.50) EPS for the quarter. The company had revenue of $99.61 million for the quarter. Zai Lab had a negative net margin of 39.29% and a negative return on equity of 24.32%. On average, research analysts expect that Zai Lab Limited Unsponsored ADR will post -2.23 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Weiss Ratings upgraded Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. JPMorgan Chase & Co. decreased their price objective on Zai Lab from $39.00 to $32.00 and set an “overweight” rating on the stock in a report on Wednesday, March 18th. Wall Street Zen downgraded Zai Lab from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Citigroup cut their target price on shares of Zai Lab from $47.00 to $44.00 and set a “buy” rating for the company in a report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $45.83.

Institutional Investors Weigh In On Zai Lab

An institutional investor recently raised its stake in Zai Lab stock. SG Americas Securities LLC lifted its stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 10,396 shares of the company’s stock after purchasing an additional 642 shares during the quarter. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 at the end of the most recent reporting period. 41.65% of the stock is owned by hedge funds and other institutional investors.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.